Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

MicroRNA-101 can block autophagy in cancer cells

All cells in our body have a system that can handle cellular waste and release building blocks for recycling. The underlying mechanism is called autophagy and literally means "self-eating". Many cancer cells have increased the activity of this system and the increased release of building blocks equip the cancer cells with a growth advantage and can render them resistant towards treatment.

10 Oct 2011

Liver cancer incidence rates continue to rise in North America

A new study finds liver cancer incidence rates continue to increase in some low-risk parts of the world such as North America, and are decreasing in some of the highest risk countries of Asia.

7 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

Combination therapy improves outcomes for liver cancer patients: Study

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.

1 Oct 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Tobacco companies deliberately kept findings of cancer-causing radioactive particles from the public

Tobacco companies knew that cigarette smoke contained radioactive alpha particles for more than four decades and developed "deep and intimate" knowledge of these particles' cancer-causing potential, but they deliberately kept their findings from the public, according to a new study by UCLA researchers.

29 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

New research shows liver transplantation candidates without hepatocellular carcinoma (HCC) derive a greater survival benefit from a living donor liver transplant (LDLT) than waiting for a deceased donor liver transplant.

28 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Patients with liver disease may now access UCSD's new Nevada clinic

Patients in Nevada seeking care for liver disease may now access the university-level expertise of UC San Diego Health System's Center for Hepatobiliary Disease and Abdominal Transplantation.

25 Aug 2011

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

Two scientists from the University of Hawaii Cancer Center and The Queen's Medical Center have received a five-year $2.3 million grant from the National Cancer Institute to develop novel methods that can better detect liver cancer through the joint analysis of gene expression and imaging data of the liver.

24 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

Should we be screening blood for hepatisi G?

Hepatitis G virus was identified in 1995. Some little research was carried out on the virus and the US Food and Drug Administration (FDA) declared it a non-harmful virus in 1997. Researchers in Saudi Arabia, writing in the International Journal of Immunological Studies present evidence to suggest that this may have been the wrong decision.

22 Aug 2011

Saffron promotes apoptosis and inhibits growth of cancerous cells

New research suggests that saffron provides a significant chemopreventive effect against liver cancer in animal models. When saffron was administered to rats with diethylnitrosamine (DEN)-induced liver cancer an inhibition of cell proliferation and stimulation of apoptosis was observed. Full findings appear in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Aug 2011

Liver Cancer News and Research

Further Reading

MicroRNA-101 can block autophagy in cancer cells

Liver cancer incidence rates continue to rise in North America

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Combination therapy improves outcomes for liver cancer patients: Study

Blueberry powder may control triple negative breast cancer

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Tobacco companies deliberately kept findings of cancer-causing radioactive particles from the public

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Engineered virus shows promise in cancer therapy via bloodstream

Patients with liver disease may now access UCSD's new Nevada clinic

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

Survival for patients with HCC increases with radioembolization

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Should we be screening blood for hepatisi G?

Saffron promotes apoptosis and inhibits growth of cancerous cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News